Todralazine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584283

CAS#: 14679-73-3

Description: Todralazine is an antihypertensive agent with both central and peripheral action; it has some central nervous system depressant effects.

Chemical Structure

img
Todralazine
CAS# 14679-73-3
Instruction

Theoretical Analysis

MedKoo Cat#: 584283
Name: Todralazine
CAS#: 14679-73-3
Chemical Formula: C11H12N4O2
Exact Mass: 232.10
Molecular Weight: 232.243
Elemental Analysis: C, 56.89; H, 5.21; N, 24.12; O, 13.78

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Todralazine

IUPAC/Chemical Name: Carbazic acid, 3-(1-phthalazinyl)-, ethyl ester

InChi Key: WGZDBVOTUVNQFP-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H12N4O2/c1-2-17-11(16)15-14-10-9-6-4-3-5-8(9)7-12-13-10/h3-7H,2H2,1H3,(H,13,14)(H,15,16)

SMILES Code: O=C(OCC)NNC1=NN=CC2=C1C=CC=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 232.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Dimri M, Joshi J, Chakrabarti R, Sehgal N, Sureshbabu A, Kumar IP. Todralazine protects zebrafish from lethal effects of ionizing radiation: role of hematopoietic cell expansion. Zebrafish. 2015 Feb;12(1):33-47. doi: 10.1089/zeb.2014.0992. Epub 2014 Dec 17. PubMed PMID: 25517940; PubMed Central PMCID: PMC4298150.

2: Gasiorowski K, Brokos B. Evaluation of antimutagenic effect of todralazine in cultured lymphocytes. Mutagenesis. 2000 Mar;15(2):137-41. PubMed PMID: 10719039.

3: Gasiorowski K, Szyba K, Wozniak D, Gulanowski B. Inhibition of potassium dichromate mutagenicity by todralazine. Mutagenesis. 1997 Nov;12(6):411-5. PubMed PMID: 9412993.

4: Elsharkawy AM. Todralazine hepatotoxicity: a sting in the histone tail. J Hepatol. 2007 Feb;46(2):189-92. Epub 2006 Dec 1. PubMed PMID: 17161489.

5: Jastrzebski Z, Czyzewska-Szafran H, Goźlińska B, Wutkiewicz M, Jedrych A, Fijałek Z, Biniecki K, Aranjo P, Ciszewski L, Mazurek AP. Acute systemic toxicity and antihypertensive activity of a novel todralazine analog in rats. Acta Pol Pharm. 1993;50(4-5):327-30. PubMed PMID: 8036918.

6: Gasiorowski K, Szyba K, Sawicka J, Gulanowski B. Mutagenicity of B(a)P in the presence of some hydralazine derivatives. Pol J Occup Med Environ Health. 1993;6(4):383-9. PubMed PMID: 8019200.

7: Gomez de Balugera Z, Arantzazu Goicolea M, Barrio RJ. Joint determination of todralazine and acetazolamide in human serum by differential pulse polarography. J Pharm Biomed Anal. 1994 Jul;12(7):883-7. PubMed PMID: 7981316.

8: Gasiorowski K, Szyba K, Sawicka J, Gulanowski B. Evaluation of the mechanisms of todralazine effect on mutagenicity of benzo(a)pyrene. Int J Occup Med Environ Health. 1995;8(3):267-73. PubMed PMID: 8581334.

9: Olczyk K, Kucharz EJ, Drózdz M. Influence of long-term treatment with hydrazinophthalazines on the activity of lysosomal exoglycosidases in rat tissues. Acta Med Hung. 1988;45(2):161-9. PubMed PMID: 3266791.

10: Reiterer W, Czitober H. [The influence of guanazodine and todralazine on blood pressure regulation during dynamic and static exercise in essential hypertension (author's transl)]. Arzneimittelforschung. 1977;27(11):2163-7. German. PubMed PMID: 580022.

11: Gasiorowski K, Gulanowski B, Szyba K, Urban J. Study of the mechanism of todralazine antimutagenic activity: the effect upon mutagenicity of daunorubicine. Int J Occup Med Environ Health. 1994;7(4):371-8. PubMed PMID: 7719664.

12: Gasiorowski K, Szyba K, Urban J. Todralazine influence upon the mutagenicity of some direct- and indirect-acting mutagens. Mutat Res. 1994 Jul;324(3):133-7. PubMed PMID: 7517512.

13: Murata K, Hamada M, Sugimoto K, Nakano T. A novel mechanism for drug-induced liver failure: inhibition of histone acetylation by hydralazine derivatives. J Hepatol. 2007 Feb;46(2):322-9. Epub 2006 Nov 3. PubMed PMID: 17156885.

14: Gasiorowski K, Brokos B. DNA repair of hydrogen peroxide-induced damage in human lymphocytes in the presence of four antimutagens. A study with alkaline single cell gel electrophoresis (comet assay). Cell Mol Biol Lett. 2001;6(4):897-911. PubMed PMID: 11753436.

15: Kedrowa S, Markiewicz M, Kolber-Postepska B, Kudlicki J. [Hypotensive action of binazine in the light of our studies]. Wiad Lek. 1980 Mar 15;33(6):421-6. Polish. PubMed PMID: 7385877.

16: Gasiorowski K, Brokos B, Kulma A, Ogorzałek A, Skórkowska K. Impact of four antimutagens on apoptosis in genotoxically damaged lymphocytes in vitro. Cell Mol Biol Lett. 2001;6(3):649-75. PubMed PMID: 11598640.

17: Cybulska I. [Phthalazine derivatives in the treatment of arterial hypertension]. Kardiol Pol. 1981;24(10):709-15. Polish. PubMed PMID: 7329009.

18: Weglarz L, Drózdz M, Wardas M. Influence of hydrazinophthalazines on the activity of collagenase in murine fibroblast culture. Biomed Biochim Acta. 1990;49(4):289-91. PubMed PMID: 2169725.

19: Falase AO, Salako LA. Clinical experience with a new vasodilator, binazine, in Nigerian hypertensives. Niger Med J. 1979 May-Jun;9(5-6):577-84. PubMed PMID: 525046.

20: Dohi Y, Kojima M, Sato K. Benidipine improves endothelial function in renal resistance arteries of hypertensive rats. Hypertension. 1996 Jul;28(1):58-63. PubMed PMID: 8675265.